An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors

Maria L. Amador, Darin Oppenheimer, Sofia Perea, Anirban Maitra, George Cusati, Christi Iacobuzio-Donahue, Sharyn D. Baker, Raheela Ashfaq, Chris Takimoto, Arlene A. Forastiere, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

This study tested the hypothesis that the number of CA single sequence repeat (CA-SSR) in the intron 1 of the epidermal growth factor receptor (egfr) gene, which affects transcription efficiency of the gene, is associated with the response to EGFR inhibitors. To this end, we determined the number of CA dinucleotides in the intron 1 of the egfr gene in a panel of 12 head and neck cancer cell lines that lack egfr gene amplification and measured the expression of EGFR (mRNA and protein), as well as response to EGFR inhibition. Cells with lower number of CA dinucleotides in the CA-SSR had higher expression of the EGFR gene and protein and were more sensitive to the inhibitory effects of erlotinib, a small molecule inhibitor of the EGFR tyrosine-kinase. Phenotypic modification by silencing EGFR mRNA expression in a susceptible cell line induced resistance to the drug. The number of CA dinucleotide was equivalent in genomic and tumor DNA obtained from 30 patients with head and neck cancer. In a clinical study in colorectal cancer, subjects with lower number of CA dinucleotide frequently developed skin toxicity, a feature that is related to the antitumor activity of this class of drugs. These results suggest that polymorphic variations in the intron 1 of the egfr gene is associated with response to EGFR inhibitors and may provide an explanation as to why the development of skin toxicity is associated with a favorable outcome in patients treated with these agents.

Original languageEnglish (US)
Pages (from-to)9139-9143
Number of pages5
JournalCancer Research
Volume64
Issue number24
DOIs
StatePublished - Dec 15 2004

Fingerprint

erbB-1 Genes
Epidermal Growth Factor Receptor
Introns
Head and Neck Neoplasms
Cell Line
Messenger RNA
Skin
Gene Amplification
Drug Resistance
Protein-Tyrosine Kinases
Colorectal Neoplasms
Proteins
DNA
Pharmaceutical Preparations
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Amador, M. L., Oppenheimer, D., Perea, S., Maitra, A., Cusati, G., Iacobuzio-Donahue, C., ... Hidalgo, M. (2004). An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Research, 64(24), 9139-9143. https://doi.org/10.1158/0008-5472.CAN-04-1036

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. / Amador, Maria L.; Oppenheimer, Darin; Perea, Sofia; Maitra, Anirban; Cusati, George; Iacobuzio-Donahue, Christi; Baker, Sharyn D.; Ashfaq, Raheela; Takimoto, Chris; Forastiere, Arlene A.; Hidalgo, Manuel.

In: Cancer Research, Vol. 64, No. 24, 15.12.2004, p. 9139-9143.

Research output: Contribution to journalArticle

Amador, ML, Oppenheimer, D, Perea, S, Maitra, A, Cusati, G, Iacobuzio-Donahue, C, Baker, SD, Ashfaq, R, Takimoto, C, Forastiere, AA & Hidalgo, M 2004, 'An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors', Cancer Research, vol. 64, no. 24, pp. 9139-9143. https://doi.org/10.1158/0008-5472.CAN-04-1036
Amador, Maria L. ; Oppenheimer, Darin ; Perea, Sofia ; Maitra, Anirban ; Cusati, George ; Iacobuzio-Donahue, Christi ; Baker, Sharyn D. ; Ashfaq, Raheela ; Takimoto, Chris ; Forastiere, Arlene A. ; Hidalgo, Manuel. / An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. In: Cancer Research. 2004 ; Vol. 64, No. 24. pp. 9139-9143.
@article{9284f36ffa674a7c9e4042c3d588d145,
title = "An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors",
abstract = "This study tested the hypothesis that the number of CA single sequence repeat (CA-SSR) in the intron 1 of the epidermal growth factor receptor (egfr) gene, which affects transcription efficiency of the gene, is associated with the response to EGFR inhibitors. To this end, we determined the number of CA dinucleotides in the intron 1 of the egfr gene in a panel of 12 head and neck cancer cell lines that lack egfr gene amplification and measured the expression of EGFR (mRNA and protein), as well as response to EGFR inhibition. Cells with lower number of CA dinucleotides in the CA-SSR had higher expression of the EGFR gene and protein and were more sensitive to the inhibitory effects of erlotinib, a small molecule inhibitor of the EGFR tyrosine-kinase. Phenotypic modification by silencing EGFR mRNA expression in a susceptible cell line induced resistance to the drug. The number of CA dinucleotide was equivalent in genomic and tumor DNA obtained from 30 patients with head and neck cancer. In a clinical study in colorectal cancer, subjects with lower number of CA dinucleotide frequently developed skin toxicity, a feature that is related to the antitumor activity of this class of drugs. These results suggest that polymorphic variations in the intron 1 of the egfr gene is associated with response to EGFR inhibitors and may provide an explanation as to why the development of skin toxicity is associated with a favorable outcome in patients treated with these agents.",
author = "Amador, {Maria L.} and Darin Oppenheimer and Sofia Perea and Anirban Maitra and George Cusati and Christi Iacobuzio-Donahue and Baker, {Sharyn D.} and Raheela Ashfaq and Chris Takimoto and Forastiere, {Arlene A.} and Manuel Hidalgo",
year = "2004",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-04-1036",
language = "English (US)",
volume = "64",
pages = "9139--9143",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors

AU - Amador, Maria L.

AU - Oppenheimer, Darin

AU - Perea, Sofia

AU - Maitra, Anirban

AU - Cusati, George

AU - Iacobuzio-Donahue, Christi

AU - Baker, Sharyn D.

AU - Ashfaq, Raheela

AU - Takimoto, Chris

AU - Forastiere, Arlene A.

AU - Hidalgo, Manuel

PY - 2004/12/15

Y1 - 2004/12/15

N2 - This study tested the hypothesis that the number of CA single sequence repeat (CA-SSR) in the intron 1 of the epidermal growth factor receptor (egfr) gene, which affects transcription efficiency of the gene, is associated with the response to EGFR inhibitors. To this end, we determined the number of CA dinucleotides in the intron 1 of the egfr gene in a panel of 12 head and neck cancer cell lines that lack egfr gene amplification and measured the expression of EGFR (mRNA and protein), as well as response to EGFR inhibition. Cells with lower number of CA dinucleotides in the CA-SSR had higher expression of the EGFR gene and protein and were more sensitive to the inhibitory effects of erlotinib, a small molecule inhibitor of the EGFR tyrosine-kinase. Phenotypic modification by silencing EGFR mRNA expression in a susceptible cell line induced resistance to the drug. The number of CA dinucleotide was equivalent in genomic and tumor DNA obtained from 30 patients with head and neck cancer. In a clinical study in colorectal cancer, subjects with lower number of CA dinucleotide frequently developed skin toxicity, a feature that is related to the antitumor activity of this class of drugs. These results suggest that polymorphic variations in the intron 1 of the egfr gene is associated with response to EGFR inhibitors and may provide an explanation as to why the development of skin toxicity is associated with a favorable outcome in patients treated with these agents.

AB - This study tested the hypothesis that the number of CA single sequence repeat (CA-SSR) in the intron 1 of the epidermal growth factor receptor (egfr) gene, which affects transcription efficiency of the gene, is associated with the response to EGFR inhibitors. To this end, we determined the number of CA dinucleotides in the intron 1 of the egfr gene in a panel of 12 head and neck cancer cell lines that lack egfr gene amplification and measured the expression of EGFR (mRNA and protein), as well as response to EGFR inhibition. Cells with lower number of CA dinucleotides in the CA-SSR had higher expression of the EGFR gene and protein and were more sensitive to the inhibitory effects of erlotinib, a small molecule inhibitor of the EGFR tyrosine-kinase. Phenotypic modification by silencing EGFR mRNA expression in a susceptible cell line induced resistance to the drug. The number of CA dinucleotide was equivalent in genomic and tumor DNA obtained from 30 patients with head and neck cancer. In a clinical study in colorectal cancer, subjects with lower number of CA dinucleotide frequently developed skin toxicity, a feature that is related to the antitumor activity of this class of drugs. These results suggest that polymorphic variations in the intron 1 of the egfr gene is associated with response to EGFR inhibitors and may provide an explanation as to why the development of skin toxicity is associated with a favorable outcome in patients treated with these agents.

UR - http://www.scopus.com/inward/record.url?scp=10844264628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10844264628&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-1036

DO - 10.1158/0008-5472.CAN-04-1036

M3 - Article

VL - 64

SP - 9139

EP - 9143

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -